#18 – Richard Isaacson, M.D.: Alzheimer's prevention

Isaacson describes seeing a patient's LDL particle number and simultaneously thinking about their executive function domain score; metabolic status correlates with specific cognitive domain impairments in his clinical observation data. Visceral fat correlates with memory; cholesterol abnormalities correlate with executive function. These are not yet published findings but are testable hypotheses emerging from his 1,000-patient registry. The four-page personalized plan generated from this assessment is the output patients leave with.

Isaacson's personal protocol: spin 3–4 mornings per week at Flywheel or Peloton, tracking torque and output numbers to ensure competitive effort; weight training once per week with a goal of twice. He acknowledges he should be doing more resistance work. The population-level evidence is 'aerobic mostly' but the mechanistic reason muscle protects the brain is likely through circulating IGF factors and glucose disposal. A person on the elliptical at 80–90 bpm watching television is not exercising in any sense relevant to brain health.

Isaacson describes the clinical workflow: patient taking standard B-vitamins, homocysteine not coming down — raise suspicion for MTHFR variant, switch to methylfolate + methyl B12 combination, homocysteine normalizes reliably. He calls it 'the yellow bottle — it always works.' He connects this to the broader MTHFR × APOE matrix that maps genotype to cognitive domain weakness — one of the most-validated precision-medicine branches in his unpublished registry data.

Isaacson frames this as one of his biggest methodological frustrations: '$75,000 would have given me the right biomarkers to definitively say which omega-3 to take.' He also applies the precision-medicine lens: giving omega-3 to everyone dilutes study results. Enrollment criterion should be omega-3 deficiency. APOE4 patients appear to benefit most from DHA supplementation.

Isaacson calls Sprint Mind 'a major major important study that needs to be on every neurologist's reading list.' He uses the 19% MCI reduction as a foundation and stacks other interventions on top. Each modifiable risk factor addressed independently moves the needle; combined they compound.

Robert Krikorian at Cincinnati is cited as a pioneer in blueberry-cognition research. The active compound question remains open: whole fruit, powder, or isolated anthocyanin? The bigger belly/smaller hippocampus relationship is the metabolic mechanism behind the nutritional prescription — adiposity directly drives hippocampal atrophy. Sitting is called 'the new smoking' for brain health.

Isaacson watches CD50 levels in Theracurmin-treated patients: TNF-alpha stays flat but CD50 rises. He doesn't know the exact interpretation but notes 'their memories not getting worse.' Multiple companies entered the market after the Japanese company that developed the original formulation went out of business — brand quality assurance matters.

Isaacson gives the clinical example: a teacher with Alzheimer's masked by a cognitively engaged life and a supportive spouse. When the spouse died, the teacher declined exponentially — the support system functioned as a cognitive prosthesis. Musical training covers multiple brain areas simultaneously and builds multimodal associative pathways more efficiently than any single-domain cognitive activity.

Isaacson describes three stages: preclinical Alzheimer's (47M, no symptoms, amyloid present), MCI due to Alzheimer's (gray zone), and dementia due to Alzheimer's (~5M). The 40-year window between pathology onset and clinical symptoms is the prevention window. Practically, this means the woman at the cocktail party who is 30 with a family history already needs to act. Isaacson's clinic at Cornell is explicitly structured as a prevention clinic — patients must have normal cognitive function with a family history to enroll.

Isaacson notes that two APOE4 copies absolutely does not mean you will get the disease — it is a polygenic risk multiplier, not a deterministic gene. He points to the PRESENILIN-1, PRESENILIN-2, and APP mutations as the only near-deterministic genes for early-onset Alzheimer's (less than 1% of cases). He has a 27-year-old PRESENILIN-1 patient for whom he is already building a 20-year prevention protocol. He tells APOE4 patients: 'I'm actually more optimistic when they come in because at least I know what I'm up against.'

Isaacson's research program at Cornell includes a Program Project studying women aged 40–65 through the menopause transition to identify the 'critical window of opportunity' for intervention. He is cautious about prescribing HRT himself (outside his scope) but refers to a reproductive endocrinologist in Texas, and his off-the-shelf position is that 'early in the perimenopause transition for the first two to five maybe seven years hormone replacement may be a good idea.' Transdermal delivery is likely better than oral given first-pass hepatic effects. The bioenergetics hypothesis also aligns with the 'type 3 diabetes / brain diabetes' framing — both paths converge on mitochondrial dysfunction.

Isaacson found this precision-medicine link through his 1,000-patient registry: MTHFR + homocysteine elevation + APOE genotype combinations map to specific cognitive domain deficits and respond differently to intervention. The B-vitamin + omega-3 interaction is critical — B-vitamin therapy only slows brain atrophy when omega-3 levels are concurrently optimized (DHA/EPA, not ALA). This is a precision-medicine example: give the wrong B-vitamin form and you see no response; give methylfolate + methyl B12, homocysteine normalizes within weeks.

Isaacson calls this a 'major major important study in the field.' The Sprint Mind finding updates the traditional fear that aggressive BP lowering in older patients would cause syncope or falls — the study showed no excess adverse events. Isaacson frames the 19% MCI reduction as the baseline onto which his other precision-medicine interventions (exercise, nutrition, omega-3, B-vitamins, sleep) can stack. Each modifiable risk factor addressed independently moves the needle; combined they add up.

Isaacson uses Theracurmin selectively in high-risk patients — particularly those with APOE4 and the TNF-alpha gene combination that drives an inflammatory cascade. He is watching CD50 levels as a proxy biomarker (TNF-alpha is not changing but CD50 is rising in treated patients). He stresses this is not a one-size-fits-all supplement: he uses it when the patient's precision-medicine profile supports it, not as universal prevention. His disclosure is clean — he has no supplement company relationships.

Isaacson ties this to early life musical training (multimodal brain engagement — parietal lobe, left language areas, visual cortex working together) and sustained social relationships. He gives the clinical example: 'I knew she had it but the husband was covering for her, and when the husband died she declined absolutely exponentially.' The social brain prosthesis disappears and the reserve is suddenly unmasked.

Isaacson explains the triangulation: never treat a lab in isolation. A fasting glucose of 97 triggers concern only when combined with elevated visceral fat (anthropometrics) and impaired memory (cognitive testing) — the ABC triangle. The glucose reading alone is weak signal; all three convergent is a call to action. He also uses HbA1c, fasting insulin, and HOMA-IR, noting that Attia's oral glucose tolerance test would be ideal but is impractical at the scale of his clinic.